Robust TMTT Growth to Drive Edwards Lifesciences' Q2 Earnings

Core Viewpoint - Edwards Lifesciences Corp. is set to report its second-quarter 2025 results on July 24, with expectations of revenue and earnings declines compared to the previous year [1][2]. Q2 Estimates - The Zacks Consensus Estimate for revenues is $1.49 billion, indicating an 8.9% decline from the prior year's figure [2]. - The estimate for net earnings is 62 cents per share, reflecting an 11.4% decrease from the year-ago reported figure [2]. Estimate Revision Trend - Earnings estimates have remained unchanged at 62 cents per share over the past 60 days, indicating stability in expectations ahead of the earnings announcement [3]. Factors at Play - The Transcatheter Aortic Valve Replacement (TAVR) segment is expected to perform well in the U.S. due to the SAPIEN 3 Ultra RESILIA platform, with a projected revenue of $1.09 billion, representing a 5.2% year-over-year increase [4][5]. - The TMTT segment is anticipated to show significant growth, with revenues estimated at $130.4 million, a 57.1% improvement from the previous year, driven by the PASCAL and EVOQUE systems [6][8]. Segment Performance - The Surgical Structural Heart segment is expected to report revenues of $263.1 million, suggesting a modest 6.2% rise from the year-ago quarter, supported by the global adoption of the RESILIA portfolio [10][11]. - The commercial launch of the EVOQUE tricuspid replacement system is likely to have progressed well, aided by Medicare coverage [7]. Earnings Whispers - Edwards has an Earnings ESP of 0.00%, indicating no advantage in beating estimates this quarter [12]. - The company currently holds a Zacks Rank of 2 (Buy), suggesting a favorable outlook compared to other stocks [13].